Search - tctmd.com

Displaying 41 - 60 of 135

Sort: Relevancy | Date

Presentation Fellows 2019

Essentials of Clinical Trial Design

Presenter: David J. Cohen

April 12, 2019

Presentation TCT 2018

Pathways for Same-Day PCI Discharge

Presenter: David A. Cox, Dmitriy N. Feldman, Mauricio G. Cohen

September 24, 2018

Presentation TCT 2018

Non-Inferiority Trials Gone Wrong: Examples From the Recent Literature

Presenter: Peter Juni, Robert W. Yeh, David J. Cohen

September 23, 2018

Presentation TCT 2018

PCI for Ischemia Part II: Why the ISCHEMIA Trial Might be Positive..or Negative!

Presenter: David J. Cohen, Sunil V. Rao, Ajay J. Kirtane

September 22, 2018

Presentation TCT 2018

PCI for Ischemia Part I: Critical Analysis of the FAME Trials and ORBITA

Presenter: David J. Cohen, Sunil V. Rao, Bernard J. Gersh

September 22, 2018

Presentation TCT 2018

Increasing Emphasis on QOL Outcomes: From Patient Preference to Instrument Validation

Presenter: David J. Cohen, Sunil V. Rao, John A. Spertus

September 22, 2018

Presentation TCT 2018

Optimal Medical Therapy With and Without Coronary Revascularization: Which Drugs Matter? Symptoms, Ischemia, or Prognosis? And Magnitude of Impact

Presenter: David J. Cohen, Sunil V. Rao, David J. Maron

September 22, 2018

Presentation The Structural Heart Disease Summit 2018

Keynote Lecture #3: A Deep Dive Into TAVR Cost-effectiveness Studies - Take-home Messages

Presenter: David J. Cohen

June 22, 2018

Presentation TCT 2017

DECISION-CTO and EURO-CTO: Critique and Unanswered Questions

Presenter: David J. Cohen, Ajay J. Kirtane, Emmanouil S. Brilakis

November 01, 2017

Presentation TCT 2017

DECISION-CTO and EURO-CTO: Topline Findings and Practice Implications

Presenter: David J. Cohen, Ajay J. Kirtane, Gerald S. Werner

November 01, 2017

Presentation TCT 2017

AIDA: Critique and Unanswered Questions

Presenter: David J. Cohen, Ajay J. Kirtane, Debabrata Mukherjee

November 01, 2017

Presentation TCT 2017

AIDA: Topline Findings and Practice Implications

Presenter: David J. Cohen, Ajay J. Kirtane, Jose P.S. Henriques

November 01, 2017

Presentation TCT 2017

DEFINE FLAIR/SWEDEHEART: Critique and Unanswered Questions

Presenter: David J. Cohen, Ajay J. Kirtane, Habib Samady

November 01, 2017

Presentation TCT 2017

DEFINE FLAIR/SWEDEHEART: Topline Findings and Practice Implications

Presenter: David J. Cohen, Ajay J. Kirtane, Thomas Engstroem

November 01, 2017

Presentation TCT 2017

Options for Aortic Stenosis and Prosthesis-Patient Mismatch: Reoperation, Fracture, Supra-annular Valve, Balloon Valvuloplasty, Other

Presenter: Alfredo Trento, David J. Cohen

November 01, 2017

Presentation TCT 2017

Identifying the Futile Severe AS Patient - Who Shouldnt Be Treated With TAVR?

Presenter: Bernard Prendergast, Brian K. Whisenant, David J. Cohen

November 01, 2017

Presentation TCT 2017

PARTNER 2A and SAPIEN 3 Cost-effectiveness: Cost-effectiveness of TAVR vs SAVR in Intermediate-Risk Patients With Aortic Stenosis

Presenter: Patrick W. Serruys, David J. Cohen

October 31, 2017

Presentation TCT 2017

Case #5: Tamponade in the Post-CABG Patient (With Discussion)

Presenter: Mauricio G. Cohen, Simon R. Dixon, David Daniels

October 30, 2017

Presentation TVT 2017

Is the Current Practice of Watchful Waiting in Severe AS a Viable Strategy in the Future?

Presenter: David J. Cohen, Jeffrey J. Popma, Robert O. Bonow

June 16, 2017

Presentation TVT 2017

Rationale and Status Update of the EARLY TAVR Trial Asymptomatic Severe AS Patients

Presenter: David J. Cohen, Jeffrey J. Popma, Philippe Généreux

June 16, 2017

Advertisement

Essentials of Clinical Trial Design

Pathways for Same-Day PCI Discharge

Non-Inferiority Trials Gone Wrong: Examples From the Recent Literature

PCI for Ischemia Part II: Why the ISCHEMIA Trial Might be Positive..or Negative!

PCI for Ischemia Part I: Critical Analysis of the FAME Trials and ORBITA

Increasing Emphasis on QOL Outcomes: From Patient Preference to Instrument Validation

Optimal Medical Therapy With and Without Coronary Revascularization: Which Drugs Matter? Symptoms, Ischemia, or Prognosis? And Magnitude of Impact

Keynote Lecture #3: A Deep Dive Into TAVR Cost-effectiveness Studies - Take-home Messages

DECISION-CTO and EURO-CTO: Critique and Unanswered Questions

DECISION-CTO and EURO-CTO: Topline Findings and Practice Implications

AIDA: Critique and Unanswered Questions

AIDA: Topline Findings and Practice Implications

DEFINE FLAIR/SWEDEHEART: Critique and Unanswered Questions

DEFINE FLAIR/SWEDEHEART: Topline Findings and Practice Implications

Options for Aortic Stenosis and Prosthesis-Patient Mismatch: Reoperation, Fracture, Supra-annular Valve, Balloon Valvuloplasty, Other

Identifying the Futile Severe AS Patient - Who Shouldnt Be Treated With TAVR?

PARTNER 2A and SAPIEN 3 Cost-effectiveness: Cost-effectiveness of TAVR vs SAVR in Intermediate-Risk Patients With Aortic Stenosis

Case #5: Tamponade in the Post-CABG Patient (With Discussion)

Is the Current Practice of Watchful Waiting in Severe AS a Viable Strategy in the Future?

Rationale and Status Update of the EARLY TAVR Trial Asymptomatic Severe AS Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content